Table 3.

Clinical outcomes according to changes in circulating PD-1 + regulatory T cells

Variable		Patients with increased circulating PD-1 + regulatory T cells (N = 26)	Patients with decreased circulating PD-1 + regulatory T cells (N = 42)	P value
Response	PR	2 (7.7)	11 (26.2)	0.021
	SD	6 (23.1)	16 (38.1)
	PD	18 (69.2)	15 (35.7)
Disease control rate		30.8%	64.3%	0.007
PseudoPD/HyperPD	Pseudoprogression	1 (3.8)	7 (16.7)	0.111
	Hyperprogression	4 (15.4)	1 (2.4)	0.046
Immune-related AEs	Any grade	8 (30.8)	13 (31.0)	0.987
	Severe AEs	7 (26.9)	8 (19.0)	0.447

Abbreviations: PR partial response, SD stable disease, PD progression disease, PseudoPD pseudoprogression, HyperPD hyperprogression, AEs adverse events